CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 93 enrolled
Drug / intervention
Galantamine +1 moredrug
Likely dose
Galantamine 8mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01531153
NCT01531153N/ACompleted
CompareCT.gov

Cognitive Enhancement as a Target for Cocaine Pharmacotherapy

Yale University·interventional·Posted Feb 10, 2012·Updated Oct 26, 2018

In Brief

A clinical study evaluating Galantamine and Placebo for Addiction. Completed, enrolled 93 participants across 1 site.

Detailed Summary

Specific Aim #1: To determine if galantamine (8 or 16 mg/day) is more effective than placebo in reducing cocaine use as measured by cocaine urine results and self-report days of use. Specific Aim # 2: To determine if galantamine (8 or 16 mg/day) is more effective than placebo in improving attention, assessed with the Rapid Visual Information Processing (RVIP) and the Simple Reaction Time (SRT) tests Specific Aim # 3: To determine if improvement in attention during the first four weeks of treatment will mediate galantamine's efficacy in reducing cocaine use.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAddiction
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA)

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedFeb 10, 2012
Enrollment StartSep 1, 2011
Primary CompletionJun 1, 2016
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 14.4 years ago

Interventions

Galantaminedrug

8mg or 16mg

Placebodrug

Placebo dose.